Skip to Content
  1. All products
  2. Cagrilintide
  3. All products
Pricelist: Default Pricelist Pricelist
Pricelist: Default Pricelist Pricelist
Cagrilintide

Cagrilintide

Lyophilized Vial · Subcutaneous Store refrigerated at 2-8 C and protect from heat and light. 99% Purity · USP Grade
99% Purity
PHYSICIAN USE ONLY
$ 83.00 $ 83.00

Format
💉 vial
  • Strength
Add to cart
Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days
Clinical Description

Appetite reduction, weight loss support, gastric emptying regulation, satiety enhancement, metabolic control

Cagrilintide es un análogo de amilina de acción prolongada diseñado para reducir el apetito, retardar el vaciado gástrico y favorecer la pérdida de peso sostenida. Complementa a los agonistas de GLP-1 como Semaglutide y Tirzepatide trabajando a través de una vía separada para aumentar la saciedad y mejorar el control metabólico. Cuando se usa en combinación, puede amplificar la pérdida de grasa y al mismo tiempo ayudar a los pacientes a sentirse más llenos por más tiempo.

Clinical Indications
Performance and endurance protocolsCardiorespiratory output support plansTraining-recovery adaptation pathways
Recommended Stacking Protocols
✓
Semaglutide
Enhances satiety and weight loss results
✓
Tirzepatide
Enhances satiety and weight loss results
✓
KPV
For anti-inflammatory support
✓
AOD-9604
Targets fat metabolism

Mechanism of Action - Performance & Endurance Pathway

Targeted Signaling
Supports protocol objectives for Cagrilintide.
Clinical Modulation
Allows dose and schedule adjustments by response.
Outcome Tracking
Pairs with clinician monitoring for iterative optimization.
Starting Dose
0.1mg to 0.3mg once weekly
Initiation phase for tolerance and baseline response.
Titration
Increase slowly to 0.6mg-1.2mg weekly based on tolerance
Maintenance Range
Maintain physician-directed target
Adjust based on objective outcomes and physician review.
Suggested Dosing Notes

Dosis inicial:0,1 mg a 0,3 mg una vez a la semana

Valoración:Aumentar lentamente a 0,6 mg-1,2 mg por semana según la tolerancia.

Period Dose Phase Clinical Notes
Starting Dose 0.1mg to 0.3mg once weekly initiation Initial dose for treatment initiation
Titration Increase slowly to 0.6mg-1.2mg weekly escalation Gradual increase based on tolerance
Week 7+ Maintenance phase maintenance Maintain target dose and reassess monthly.
Preparation Protocol
  1. Cagrilintide se suministra como polvo liofilizado.
  2. Cagrilintide debe reconstituirse antes de su uso.
  3. Añadir 2 mL de agua bacteriostatica al vial. Girar suavemente para disolver. Conservar en refrigeracion tras la reconstitución.
1
Inspect vial
Confirm vial integrity, lot, and expiration before use.
2
Aseptic reconstitution
Disinfect stopper and add bacteriostatic water slowly.
3
Gentle dissolution
Swirl gently until the solution is clear and homogeneous.
4
Prepare dose
Draw dose according to reconstitution conversion guidance.
Reconstitution & Dosing Guide
Standard 1 mL insulin syringe: 100 units = 1 mL

Total Peptide: 5 mg
BW: 2 mL
Concentration: 2.5mg/mL (25mcg per unit on a 1mL insulin syringe)
Dose Units to Draw Volume (mL) Approx. Supply
0.1mg 4 units - 50 weeks
0.2mg 8 units - 25 weeks
0.3mg 12 units - 16 weeks
0.6mg 24 units - 8 weeks
0.9mg 36 units - 5 ½ weeks
1.2mg 48 units - 4 weeks
Identity
  • Product Name: Cagrilintide
  • Product Type: Vial | Subcutaneous Injection
  • Strength Options: 5 mg, 10 mg
  • Available Strengths: 5mg, 10mg
Quality & Purity
  • Purity: >= 99%
  • Sterility: Aseptic handling required
  • Purity: 99%+
Storage & Handling
  • Storage: 2-8 C refrigerated
  • Handling: Avoid heat, shaking, and direct light
  • Storage: Refrigerate after reconstitution (2-8°C)

Timing: Use consistent administration timing for stable protocol tracking.

Storage: Store refrigerated at 2-8 C and protect from heat and light.

Frequency: StartingDose:O.1mg to O.3mgonceweekly Titration:Increaseslowly to0.6mg-1.2mg weeklybased onitolerance

Cycle: Cycle length and cadence are clinician-defined per patient profile.

Injection Sites: Rotate approved injection sites to reduce local irritation risk.